Join BJS Academy
BJS Academy>Randomized clinical ...>3 year invasive dise...
Normal View Dyslexic View

3-year invasive disease-free survival with chemotherapy de-escalation using an 18F-FDG-PET-based, pathological complete response-adapted strategy in HER2-positive early breast cancer (PHERGain): a randomised, open-label, phase 2 trial.

21 June 2024
Randomized clinical trials Breast
Perez-Garcia JM, Cortes J, Ruiz-Borrego M Colleoni M, Stradella A, Bermejo B et al, on behalf of PHERGain Trial Investigators.

Lancet 2024; 403: 1649-1659.

This complex study that included 356 patients with HER2 +ve breast cancer with visible disease on PET imaging showed that around one third of patients could avoid chemotherapy and just have immunotherapy and hormonal treatment, with similar three-year survival rates.

Comment: Research that reduces the need for chemotherapy is always welcome, and refines the treatment pathway.

BJS Foundation Limited
BJS Academy
0000-0000
BJS Foundation Limited
London, UK
rct009
Randomized clinical trials
Randomized clinical trials
Breast
3-year invasive disease-free survival with chemotherapy de-escalation using an 18F-FDG-PET-based, pathological complete response-adapted strategy in HER2-positive early breast cancer (PHERGain): a randomised, open-label, phase 2 trial.
Perez-Garcia JM, Cortes J, Ruiz-Borrego M Colleoni M, Stradella A, Bermejo B et al, on behalf of PHERGain Trial Investigators.
21062024
Lancet 2024; 403: 1649-1659.
This complex study that included 356 patients with HER2 +ve breast cancer with visible disease on PET imaging showed that around one third of patients could avoid chemotherapy and just have immunotherapy and hormonal treatment, with similar three-year survival rates.
Comment: Research that reduces the need for chemotherapy is always welcome, and refines the treatment pathway.
Published on: 21 June 2024
Article ID: rct009

Related articles

Aspirin vs placebo as adjuvant therapy for breast cancer. The Alliance A011502 randomized trial.

Chen WY, Ballman KV, Partridge AH, Hahn OM, Briccetti FM et al.

16 August 2024

21-Gene assay to inform chemotherapy benefit in node-positive breast cancer.

Kalinsky K, Barlow WE, Gralow JR, Meric-Bernstam F, Albain KS, Hayes DF et al.
N Engl J Med 2021; 385: 2336-2347

1 January 2022

Event-free survival with pembrolizumab in early triple-negative breast cancer.

Schmid P, Cortes J, Dent R, Pusztai L, McArthur H, Kummel S et al, for the KEYNOTE-522 Investigators.
N Engl J Med 2022; 386: 556-567.

1 March 2022
Home
  • Normal view
  • Dyslexic view
Info
Copied!